Literature DB >> 3224080

Sensitivity of locally recurrent rat mammary tumour cell lines to syngeneic polymorphonuclear cell, macrophage and natural killer cell cytolysis.

P A Aeed1, D R Welch.   

Abstract

Using a recently developed model for studying the biology of locally recurrent (LR) mammary tumours in the 13762NF rat mammary adenocarcinoma system, we examined the sensitivity to polymorphonuclear cell, macrophage and natural killer cell cytolysis. The parental MTF7(T20) cell line; the 'primary' tumours which arose following subcutaneous inoculation into the mammary fat pad, sc1 and sc3; and the local recurrences (following surgical excision) LR1 and LR1a from sc1, and LR3 from sc3 were all cells generally resistant to specific PMN cytolysis. LPS-activated macrophages caused 25.1%, 38.7% and 58.8% specific cytolysis in MTF7, sc1 and LR1 cells, respectively at E:T of 20:1 and 72 h co-incubation. LR1a, sc3 and LR3 lysis ranged from 0-4.4% under the same conditions. Non-activated macrophages did not lyse any of the cell lines. Locally recurrent and 'primary' tumour cell lines were also not lysed by naive NK cells (range 0.5-4.0% cytolysis). NK cells activated with bropirimine, a potent immunomodulator currently being studied in clinical trials, and/or interleukin-2 were mildly more effective at killing LR cells. Our results show that locally recurrent tumours exhibit heterogeneous sensitivities and are different from 'primary' tumour cells in sensitivities to immune cell killing, but they are not necessarily more or less sensitive. Results with bropirimine-activated or IL-2-activated NK cells emphasize that nonspecific activation is insufficient to eliminate all tumour subpopulations.

Entities:  

Mesh:

Year:  1988        PMID: 3224080      PMCID: PMC2246853          DOI: 10.1038/bjc.1988.302

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  Development and characterization of a rat model for locally recurring mammary tumors: sensitivities to 5-fluoro-2'-deoxyuridine, adriamycin, and X-irradiation.

Authors:  D R Welch; P A Aeed; J Estrada
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

2.  Cytotoxic effects of peritoneal neutrophils on a syngeneic rat tumour.

Authors:  A H Pickaver; N A Ratcliffe; A E Williams; H Smith
Journal:  Nat New Biol       Date:  1972-02-09

3.  In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain.

Authors:  T R Chen
Journal:  Exp Cell Res       Date:  1977-02       Impact factor: 3.905

4.  Natural history and prognosis of recurrent breast cancer.

Authors:  S Karabali-Dalamaga; R L Souhami; N J O'Higgins; A Soumilas; C G Clark
Journal:  Br Med J       Date:  1978-09-09

5.  The significance of hematogenous tumor cell clumps in the metastatic process.

Authors:  L A Liotta; M G Saidel; J Kleinerman
Journal:  Cancer Res       Date:  1976-03       Impact factor: 12.701

6.  A biostatistical study of locally recurrent breast carcinoma.

Authors:  W L Donegan; C M Perez-Mesa; F R Watson
Journal:  Surg Gynecol Obstet       Date:  1966-03

Review 7.  Biologic considerations for drug targeting in cancer patients.

Authors:  D R Welch
Journal:  Cancer Treat Rev       Date:  1987-12       Impact factor: 12.111

8.  Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.

Authors:  L H Li; T F DeKoning; T L Wallace
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

9.  Recurrent breast cancer: factors influencing survival, including treatment.

Authors:  N W Pearlman; P R Jochimsen
Journal:  J Surg Oncol       Date:  1979       Impact factor: 3.454

10.  Influence of immune status on the metastasis of three murine fibrosarcomas of different immunogenicities.

Authors:  I J Fidler; D M Gersten; M L Kripke
Journal:  Cancer Res       Date:  1979-10       Impact factor: 12.701

View more
  1 in total

Review 1.  Biointerface engineering nanoplatforms for cancer-targeted drug delivery.

Authors:  Huaiyu Zhang; Shujun Dong; Zhongmin Li; Xiangru Feng; Weiguo Xu; Catrina Mae S Tulinao; Yang Jiang; Jianxun Ding
Journal:  Asian J Pharm Sci       Date:  2019-12-30       Impact factor: 6.598

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.